Chief Financial Officer
Chief Financial Officer at Spyre Therapeutics, Inc., filing insider transactions between 2026-08-03 and 2026-10-01.
| SEC ↗ |
| 2026-10-01 | SYRE | Sale | 2,100 | $91.92 | $193K | SEC ↗ |
| 2026-10-01 | SYRE | Sale | 1,500 | $90.27 | $135K | SEC ↗ |
| 2026-09-30 | SYRE | Sale | 17.5K | $89.89 | $1.6M | SEC ↗ |
| 2026-09-02 | SYRE | Sale | 18.2K | $89.35 | $1.6M | SEC ↗ |
| 2026-09-01 | SYRE | Sale | 2,016 | $88.03 | $177K | SEC ↗ |
| 2026-09-01 | SYRE | Sale | 900 | $86.25 | $78K | SEC ↗ |
| 2026-09-01 | SYRE | Sale | 4,384 | $87.11 | $382K | SEC ↗ |
| 2026-09-01 | SYRE | Sale | 200 | $89.04 | $18K | SEC ↗ |
| 2026-08-03 | SYRE | Sale | 2,300 | $96.30 | $221K | SEC ↗ |
| 2026-08-03 | SYRE | Sale | 5,100 | $95.21 | $486K | SEC ↗ |
| 2026-08-03 | SYRE | Sale | 100 | $97.10 | $10K | SEC ↗ |